Abnormal Circadian Modification of Aδ-Fiber Pathway Excitability in Idiopathic Restless Legs Syndrome by Vollono, Catello et al.
 
  
 
Aalborg Universitet
Abnormal Circadian Modification of A-Fiber Pathway Excitability in Idiopathic Restless
Legs Syndrome
Vollono, Catello; Della Marca, Giacomo; Testani, Elisa; Losurdo, Anna; Virdis, Daniela;
Ferraro, Diana; Brunetti, Valerio; Rossini, Paolo M; Le Pera, Domenica; Mazza, Salvatore;
Valeriani, Massimiliano
Published in:
Pain Research & Management
DOI (link to publication from Publisher):
10.1155/2019/5408732
Creative Commons License
CC BY 4.0
Publication date:
2019
Document Version
Publisher's PDF, also known as Version of record
Link to publication from Aalborg University
Citation for published version (APA):
Vollono, C., Della Marca, G., Testani, E., Losurdo, A., Virdis, D., Ferraro, D., Brunetti, V., Rossini, P. M., Le
Pera, D., Mazza, S., & Valeriani, M. (2019). Abnormal Circadian Modification of A-Fiber Pathway Excitability in
Idiopathic Restless Legs Syndrome. Pain Research & Management, 2019, [5408732].
https://doi.org/10.1155/2019/5408732
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            ? Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            ? You may not further distribute the material or use it for any profit-making activity or commercial gain
            ? You may freely distribute the URL identifying the publication in the public portal ?
Research Article
Abnormal Circadian Modification of Aδ-Fiber Pathway
Excitability in Idiopathic Restless Legs Syndrome
Catello Vollono,1 Giacomo Della Marca,1 Elisa Testani,1 Anna Losurdo,1 Daniela Virdis,1
Diana Ferraro,2 Valerio Brunetti,1 Paolo M. Rossini,1,3 Domenica Le Pera,3
Salvatore Mazza,1 and Massimiliano Valeriani 4,5
1Unit of Neurophysiopathology, Department of Geriatrics, Neurosciences and Orthopedics, Catholic University,
Policlinico Universitario “A. Gemelli” IRCCS, Rome, Italy
2Neurology Unit, Department of Neurosciences, University of Modena and Reggio Emilia, Modena, Italy
3Area Neuroscienze, San Raffaele Pisana IRCCS, Rome, Italy
4Neurology Division, Pediatric Hospital “Bambino Gesù” IRCCS, Rome, Italy
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Restless legs syndrome (RLS) is characterized by unpleasant sensations generally localized to legs, associated with an urge to move.
A likely pathogenetic mechanism is a central dopaminergic dysfunction. (e exact role of pain system is unclear. (e purpose of
the study was to investigate the nociceptive pathways in idiopathic RLS patients. We enrolled 11 patients (mean age 53.2± 19.7
years; 7 men) suffering from severe, primary RLS. We recorded scalp laser-evoked potentials (LEPs) to stimulation of different
sites (hands and feet) and during two different time conditions (daytime and nighttime). Finally, we compared the results with a
matched control group of healthy subjects. (e Aδ responses obtained from patients did not differ from those recorded from
control subjects. However, the N1 and the N2-P2 amplitudes’ night/day ratios after foot stimulation were increased in patients, as
compared to controls (N1: patients: 133.91± 50.42%; controls: 83.74± 34.45%; p � 0.016; Aδ-N2-P2: patients: 119.15± 15.56%;
controls: 88.42± 23.41%; p � 0.003). (ese results suggest that RLS patients present circadian modifications in the pain system,
which are not present in healthy controls. Both sensory-discriminative and affective-emotional components of pain experience
show parallel changes. (is study confirms the structural integrity of Aδ nociceptive system in idiopathic RLS, but it also suggests
that RLS patients present circadian modifications in the pain system. (ese findings could potentially help clinicians and
contribute to identify new therapeutic approaches.
1. Introduction
Idiopathic restless legs syndrome (RLS) is a large prevalent
chronic sensory-motor disorder [1] and it is characterized by
unpleasant sensations generally localized to legs and asso-
ciated with an urge to move. (e etiology of RLS is not fully
understood. (e most likely pathogenic mechanism consists
in a central dopaminergic dysfunction. (e symptoms
worsen or are exclusively present at rest [1]. RLS symptoms
have a circadian rhythm: they reach maximal severity at
night, when the dopamine levels are at their nadir, with
consequent disruption of sleep [2]. (e motor symptoms,
represented by an incoercible impulse to move the legs and
repetitive, spontaneous, stereotyped, voluntary, and un-
intentional movements of the legs, are present during both
wake and sleep [3].
Although there is no agreement about the prevalence of
pain in RLS, some RLS patients describe their sensations as
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painful [4]. Involvement of nociception in RLS is also
suggested by the therapeutic response to opioids and the
physiologic link between dopamine and pain control [5].
(e exact role of pain system in RLS is unclear and only
few studies addressed this issue. In patients with RLS, both
primary and secondary to large fiber neuropathy,
Schattschneider et al. found an impairment of thermal
perception threshold suggesting a small fiber involvement
[6]. Another study [7] demonstrated that symptomatic RLS
may be triggered by small fiber neuropathy. However, no
epidermal fiber abnormality was found in skin biopsies of
patients with idiopathic RLS [6]. (e lower pain threshold in
RLS patients than in control suggests that pain processing
may be amplified in this disease [8]. Lastly, hyperalgesia
associated with tactile hypoesthesia and paradoxical heat
sensation was described in RLS patients [9].
Laser-evoked potential (LEP) recording represents the
most reliable neurophysiological technique to assess the
human nociceptive system function (evidence level A) [10].
CO2 laser pulses delivered on the skin activate the noci-
ceptive Aδ and C fibers, without any stimulation of the
nonnociceptive Aβ afferents [11].
To the best of our knowledge, only one previous study
assessed the nociceptive function in RLS by using LEPs [12].
No abnormalities of both LEPs and sympathetic skin re-
sponses were found. However, the neurophysiological re-
sponses were recorded in one session; thus, the characteristic
circadian rhythm of the symptoms in RLS was not
considered.
(e aims of the present study were to investigate (1) the
function of the Az-fiber pathway in idiopathic RLS patients
by recording LEPs to stimulation of different sites (hands
and feet) and (2) possible modifications of the nociceptive
system excitability linked to the circadian rhythm of the
disease. To reach this purpose, LEPs were recorded at two
different times (early afternoon and nighttime).
2. Methods
2.1. Patients and Healthy Controls. We enrolled 11 patients
(mean age 53.2± 19.7 years; 7 men, 4 women, range 22–77
years; disease duration: 13.2± 15.6 months). RLS diagnosis
was reached by using a structured interview following the
International Restless Legs Syndrome Study Group (IRLSSG)
diagnostic criteria [13]. Severity of RLS symptoms was
measured by the IRLSSG scale [13].
Inclusion criteria were (1) primary RLS, (2) severe
symptoms (IRLSSG score> 15, mean � 30.0± 3.8), (3) ex-
clusive or prevalent involvement of lower limbs, and (4)
presence of a definite circadian pattern of symptoms.
Exclusion criteria were (1) other movement disorders, (2)
other sleep disorders, (3) neurological or medical disease,
(4) any condition associated with chronic musculoskeletal
or neuropathic pain, (5) intake of dopamine agonists,
antidopaminergic, as well as other neurological active
drugs (benzodiazepines, opioids, GABA-agonists, etc.), (6)
any condition possibly causing secondary RLS (renal dis-
ease, anemia, and pregnancy), and (7) history of alcohol or
drug abuse. All patients underwent full medical and
neurological examination and neurophysiological tests,
including measurements of nerve conduction, somato-
sensory-evoked potentials, motor-evoked potentials during
daytime and overnight, and laboratory-based poly-
somnography. (e main clinical data concerning the pa-
tients are summarized in Table 1. Clinical and instrumental
data obtained from patients were compared with those
obtained from 11 healthy volunteers, matched for sex and
age (mean age 55.4± 18.7 years; 7 males, 4 females, range
21–74 years). Data concerning the control subjects are
reported in Table 2. (e study was approved by the local
ethical committee, and all subjects gave their informed
consent to participate.
2.2. Laser Stimulation and LEP Recording. In both patients
and controls, LEP recordings were performed in two sep-
arate sessions: daytime session (on early afternoon, between
1:00 PM and 3:00 PM) and nighttime session (on evening,
between 9:00 PM and 11:00 PM). LEPs were obtained to
stimulation of both hand and foot. Right and left sides were
stimulated. Two averages of 20 trials each were obtained for
each session and each stimulation site.
During LEP recording, the subject lay on a couch in a
warm and semidarkened room. Cutaneous heat stimuli were
delivered by a CO2 laser (wavelength 10.6 μm, beam di-
ameter 2mm, duration 10 milliseconds, CO2 Neurolas
Electronic Engineering, Florence, Italy). (e stimulation site
was visualized by a He-Ne laser beam.
(e location of the impact on the skin was slightly shifted
between two successive stimuli to avoid the sensitization of
the nociceptors. (e sensory threshold (S(), defined as the
lower stimulus intensity eliciting a distinct pinprick sen-
sation, was determined by the method of limits in three
series of increasing and decreasing stimulus intensities. To
record LEPs, we used an intensity set at 2.5x S( (recording
intensity, RI), which was felt as a painful pinprick by all the
subjects. (e interstimulus interval (ISI) varied randomly
between 8 and 12 seconds. All subjects underwent a standard
recording session simultaneously gathered from 3 scalp
electrodes placed on Fz, Cz, and contralateral temporal
region (T3 or T4), defined according to the 10–20 In-
ternational System of EEG recording. (e reference elec-
trode was placed at the nose and the ground on the forehead
(Fpz). Eye movements and eye blinks were monitored by
electro-oculogram (EOG). Signals were amplified, filtered
(bandpass 0.3–70Hz), and stored for offline average and
analysis. (e analysis time was 1000 milliseconds with a bin
width of 2 milliseconds. An automatic artifact rejection
system excluded from the average procedure all trials
contaminated by transients exceeding ±65 μV at any re-
cording channel, including EOG. In order to ensure that the
attention level of subjects did not change across the whole
experiment, they were asked to count the number of the
received laser stimuli silently. Any recording with a counting
mistake higher than 10% would not be considered for
further analysis.
After each LEP recording, all subjects were asked to rate
laser pain by using a 101-point visual analog scale (VAS), in
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which “0” corresponded to no pain and “100” to the worst
pain one may conceive.
2.3. LEP Analysis. Scalp LEPs include two main compo-
nents: (1) the N1 potential, which is recorded in the temporal
region contralateral to the stimulated side, and (2) the N2-P2
complex, which shows its maximal amplitude on the vertex
(Cz). For all LEP components, peak latencies were measured.
(e peak-to-peak N2-P2 amplitude was measured. Because
in labeling the N1 reponse a certain difficulty may be caused
by noise, the N1 amplitude was calculated offline by re-
ferring the temporal electrode contralateral to the stimulated
side (T3 or T4) to the Fz lead [14].
2.4. Statistical Analysis. (e following variables were in-
cluded in the statistical analysis: VAS score, latencies, and
amplitudes of N1, N2, and P2 potentials. All measures were
compared between groups and within groups. Comparison
between groups (patients vs. controls) was performed for
each site of stimulation (hands and feet) and each stimu-
lation session (day and night). Moreover, within each group
(patients and controls), we compared the results of daytime
vs. nighttime trials for each site of stimulation (hands and
feet). Lastly, in order to evaluate modifications of the la-
tencies and amplitudes of all LEP components between the
sessions and compare these modifications between patients
and controls, all neurophysiologic measures obtained in
nighttime session were expressed as percentages of the
corresponding values recorded in daytime session,
according to the formula:
night-to-day variation �
night result
day result
× 100. (1)
(e statistical analysis was performed in successive steps.
First, the normality of the distribution of all variables by
means of the Shapiro–Wilk’s test was verified; then, non-
parametric tests (Mann–Whitney U-test) were applied to
comparisons between nonnormal distributed parameters;
lastly, the parametric Student’s t-test, or the one-way
analysis of variance (ANOVA) was used to compare normal
distributed variables.
(e significance level was set at p< 0.05. In case of
multiples comparison, in order to avoid family-wise type-I
errors, a formal Bonferroni correction was applied to each
family of comparisons, by dividing the limit of significance
by the number of comparisons (for VAS score, N1 and N2-
P2 latencies, and amplitudes, four comparisons were made:
(1) controls during day vs. controls during night, (2) patients
during day vs. patients during night, (3) controls vs. patients
during day, and (4) controls vs. patients during night;
therefore, the significance level was set at p � 0.05/4 �
0.0125). Statistics were performed using the SYSTAT 12
software, version 12.02.00 for Windows® (copyrightSYSTAT® Software Inc. 2007).
3. Results
3.1. Psychophysical Data. (e mean VAS pain rating scores
obtained in day and night sessions in patients and controls are
reported in Table 3. In the RLS group, compared to controls,
we found a significant increase of VAS score after foot
(patients: 55.64± 16.45; controls: 34.73± 15.74 U-test =
21.0; p � 0.009) and hand stimulation (patients: 55.91±
12.93; controls: 31.64± 19.76;U-test = 18.0; p � 0.005) during
night session.
Table 1: Clinical and PSG data in RLS patients.
Patient Sex Age Duration IRLSSG score Sleep latency (min) PLM index (events/h) Comorbidity
#1 M 22 4 36 61 79 HyperCKemia
#2 F 30 3 29 304 59 Overweight
#3 F 68 12 30 20 14
#4 F 70 40 35 75 121
#5 M 64 30 27 13 25
#6 M 77 5 29 12 111
#7 M 40 1 23 18 5
#8 M 27 1 27 47 96
#9 M 58 40 32 21 156 Glaucoma
#10 F 61 7 33 13 23
#11 M 68 2 29 103 247
Mean 53.2 13.2 30.0 62.3 85.1
SD 19.6 15.6 3.8 85.7 72.9
Polysomnographic data. Sleep latency: sleep-onset latency; PLM index: periodic limb movement index (number of events per hour).
Table 2: Control subjects.
CTR Sex Age Sleep latency (min) PLM index (events/h)
#1 M 60 17 5
#2 F 71 18 18
#3 M 49 11 13
#4 M 38 21 3
#5 M 74 9 0
#6 F 58 20 4
#7 F 64 25 4
#8 F 29 7 6
#9 M 71 19 4
#10 M 21 11 9
#11 M 74 14 16
Mean 55.4 15.6 7.5
SD 18.7 5.6 5.8
Polysomnographic data. Sleep latency: sleep-onset latency; PLM index:
periodic limb movement index (number of events per hour).
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3.2. Neurophysiological Data. Nerve conduction study, so-
matosensory-evoked potentials, and motor-evoked poten-
tials were normal in all RLS patients and controls.
Polysomnographic data are consistent with a severe RLS in
all patients; in particular, all patients showed high sleep-
onset latency (Table 1).
Reproducible N1 response and biphasic N2-P2 complex
were recorded in all our patients and control subjects.
Within-groups (day vs. night) and between-groups (controls
vs. patients) comparisons of LEP latencies and amplitudes
did not show significant differences (Table 4). Lastly, the
night/day ratios of all LEP components were compared
between patients and controls.(e N1 and N2-P2 amplitude
night/day ratios after foot stimulation were increased in
patients (N1: patients: 133.91± 50.42%; controls: 83.74±
34.45%; U-test� 82.0; p � 0.016; Aδ-N2-P2: patients: 119.15
± 15.56%; controls: 88.42± 23.41%; U-test� 106; p � 0.003)
(Figure 1) (Table 5).
4. Discussion
(e Aδ-fiber responses recorded after foot and hand
stimulation in all our patients did not differ from those
obtained in control subjects. (is result suggests that RLS
patients do not have a small fiber neuropathy. However,
while RLS patients showed increase of the LEP amplitudes
and pain rating values to foot stimulation in the night
compared to the day session, in control subjects, LEP am-
plitudes and VAS values decreased during the night. (is
suggests that RLS patients present circadian modifications in
the pain system, which are not present in healthy controls.
(ese circadian modifications involve both Aδ-N1 and Aδ-
N2-P2 complex responses. Since these potentials have a
different functional meaning, our findings support the in-
volvement of both the sensory-discriminative [15] and af-
fective-emotional components of pain [16].
4.1. Nociceptive System in RLS. Impairment of the noci-
ceptive system in RLS has been hypothesized and in-
vestigated [17]. (e only previous LEP study performed in
RLS patients [12] reported normal responses to nociceptive
fibers stimulation. However, RLS patients were examined
only during the day; therefore, the circadian rhythm of the
symptoms characterizing this disorder was not considered
[12]. Psychophysiological studies have reported contro-
versial results. In idiopathic RLS, Schattschneider et al.
found normal temperature perception thresholds reflecting
small fiber integrity [6]. Conversely, Stiasny-Kolster et al.
[9] described pinprick hyperalgesia, reverted by l-DOPA
treatment and associated with functional sensory loss [9].
Hyperalgesia, not associated with mechanical allodynia,
was interpreted as an atypical form of central sensitization
[9]. (e authors interpreted the RLS symptoms as ex-
pression of the flexor reflex, a circuit that represents a key
structure in the RLS phenomenology. Flexor reflex is or-
ganized as a protective device producing nociceptive
withdrawal driven by Aδ afferents. In this model, the in-
terneuronal network mediating the withdrawal responses is
connected with peripheral afferents and motor pathways.
In this way, overlapping neural systems are “parsimoni-
ously devoted to perform apparently unrelated actions such
as nociceptive withdrawal and walking. (us, this structure
encompasses the essential substrate for the distinctive
manifestations of RLS, both motor (urge to move) and
sensory (dysesthesia) [18].
4.2. Circadian Modifications of Pain. Circadian oscillations
in the pain system function are debated in healthy subjects.
While a number of human studies on experimental pain
documented significant circadian variation in pain per-
ception, other studies failed in documenting any clinically
relevant circadian variation in pain perception [19]. In a
psychophysiological study, Strian et al. [20] could only
detect small diurnal variations, characterized by high
interindividual variability, which were “not sufficient to
explain the variations seen in clinical pain.” In a more
recent study with repeated sessions of LEP recordings in
normal subjects, LEPs latencies did not show significant
modifications in nocturnal versus diurnal recordings [21].
Our findings in the control group confirm that healthy
subjects present only minimal or absent circadian fluc-
tuation of the pain systems, thus supporting the teleo-
logical sentence of Bachmann et al., according to whom
“the role of pain as a physiological protection makes
significant diurnal alterations in pain perception in
healthy humans unlikely” [21].
On the other hand, circadian rhythms in the occur-
rence and intensity of pain may be present in various
pathologic conditions, such as migraine, rheumatoid ar-
thritis, toothache, cancer, and intractable pain [19]. Also,
in fibromyalgia there is a clear diurnal rhythmicity in pain
perception [22].
Our RLS patients showed higher LEP amplitude and
higher pain perception to foot stimulation during the night
Table 3: VAS pain rating score.
Foot
Night vs. day
Hand
Night vs. day
Night Day Night Day
RLS 55.64± 16.45 49.91± 12.77 U test: 68.5
p � 0.599 55.91± 12.93 51.36± 10.92
U test: 72.5
p � 0.430
CTR 34.73± 15.74 39.18± 19.49 U test: 50.5
p � 0.511 31.64± 19.76 40.91± 20.31
U test: 54
p � 0.669
RLS vs. CTR U test: 21
p � 0.009∗
U test: 38.5
p � 0.148
U Test: 18
p � 0.005∗
U test: 42.5
p � 0.237
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Figure 1: Laser-evoked potentials (LEP) obtained after foot and hand stimulation in an RLS patient (a) and a control subject (b). (e figure
shows, in RLS patient, that both Aδ-N1 and Aδ-N2-P2 amplitudes after foot stimulation are increased during night when compared to
daytime recordings. Conversely, LEP amplitude after hand stimulation results in unmodified night and day stimulation. In control subject,
LEP amplitudes are substantially unchanged in two sessions after foot and hand stimulation.
Table 4: Neurophysiological data.
Foot
Night vs day
Hand
Night vs day
Night Day Night Day
N1 latency (ms)
RLS 149.5± 32.8 165.2± 34.2 U test: 37.5
p � 0.218 151.7± 36.6 155.7± 31.8
U test: 54
p � 0.669
CTR 172.4± 30.0 174.1± 30.0 U test: 51
p � 0.940 143.6± 24 152.3± 33.2
U test: 46
p � 0.340
RLS vs. CTR U test: 29
p � 0.112
U test: 45
p � 0.481
U test: 67.5
p � 0.646
U test: 71
p � 0.490
N1 amplitude (μV)
RLS 3.1± 1.1 2.7± 2.4 U test: 73.5
p � 0.193 3.8± 2.6 3.6± 2
U test: 54
p � 0.670
CTR 3.7± 1.5 4.8± 2.0 U test: 31.5
p � 0.162 4.5± 2.7 5.2± 1.5
U test: 43
p � 0.250
RLS vs. CTR U test: 41
p � 0.496
U test: 21
p � 0.017
U test: 48
p � 0.412
U test: 34
p � 0.082
N2 latency (ms)
RLS 226.7± 46.8 238.9± 54.4 U test: 50
p � 0.725 218.8± 54.4 234.2± 56.4
U test: 59
p � 0.922
CTR 236.8± 26.0 223.2± 33.1 U test: 62
p � 0.621 201.8± 31.2 197.5± 36.5
U test: 67
p � 0.669
RLS vs. CTR U test: 57
p � 0.888
U test: 66
p � 0.438
U test: 78
p � 0.250
U test: 86
p � 0.094
P2 latency (ms)
RLS 396.6± 83.4 372.7± 60.9 U test: 79
p � 0.224 351.8± 60.4 365.8± 72.6
U test: 84
p � 0.123
CTR 364.8± 29.9 353.2± 31.0 U Test: 71.5
p � 0.470 318.8± 37.9 322.4± 41.7
U Test:56.5
p � 0.793
RLS vs. CTR U test: 79
p � 0.224
U test: 75.5
p � 0.324
U test: 84
p � 0.123
U test: 83
p � 0.140
N2-P2 amplitude (μV)
RLS 13.6± 5.2 11.5± 4.0 U Test: 74.5
p � 0.358 10.7± 5.1 11.1± 4.7
U test: 60
p � 0.974
CRL 12.4± 7.1 15± 9.0 U test: 49
p � 0.450 14.1± 8.6 16.9± 11.1
U test: 52
p � 0.577
RLS vs. CTR U test: 74
p � 0.375
U test: 50
p � 0.490
U test: 47
p � 0.375
U test: 39
p � 0.158
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than during the day session. (ese circadian amplitude
modifications involved both the N1 and N2-P2 responses.
Intracerebral LEP recordings demonstrated that the N1
potential is generated in the secondary somatosensory area
(SII area) [23], while the N2-P2 complex is originated from
the anterior cingulate cortex (ACC) [24]. In particular, the
P2 potential may be considered as the main marker of the
genuine ACC activity, while other neural sources, such as
the bilateral SII area [25], insula [15, 26] and, maybe,
primary somatosensory area (SI area) [27], contribute to
the N2 response generation. As compared to the P2 po-
tential, the N1 response is less reduced in amplitude by
distraction from the laser stimulus; thus, it has been linked
to the sensory-discriminative component of pain [15]. On
the contrary, the vertex LEP components, in particular the
P2 potential, are extremely sensitive to cognitive factors,
e.g., distraction from the painful stimulus, and are
therefore thought to represent the neurophysiological
counterpart of the attention-affective-emotional aspect of
pain experience [16]. Given the fact that in our patients
both the N1 and the N2-P2 amplitude underwent the same
circadian modification, these results suggest that both
sensory-discriminative [15] and attention-affective-emo-
tional components of pain experience [16] undergo similar
modifications. Since the N1 and the P2 potentials are
generated by parallel spinal pathways [28], the spinal cord,
where both pathways ascend closely, may be the site of this
change. However, we cannot exclude the fact that other
regions of the central nervous system may be involved.
4.3. Mechanisms of Circadian Fluctuation of Pain in RLS.
In RLS, the circadian variations of the symptoms are
probably related to the molecular mechanisms involved in
its development. (ere are 3 main hypotheses to explain the
sensory symptom fluctuations. First, dopaminergic systems
play a major role in RLS. Dopaminergic projections to the
spinal cord originate supraspinally in dorsoposterior hy-
pothalamic area A11 [29]. (e A11 axons primarily arrive to
the dorsal horn, and project onward to the motoneuronal
site [30]. (e A11-diencephalic dopaminergic nucleus
provides the main descending dopaminergic control of the
spinal tract [31]. (e A11 diencephalo-spinal pathway is
known as a crucial structure for pain control at the spinal
cord level [32]. Two elegant studies, in animal models,
showed that A11 cell group in the hypothalamus is directly
involved in descending control of pain [33, 34]. Clemens
et al. suggested that in RLS, a dysfunction of the dopami-
nergic A11 neurons could shift the descending control to
excitation with an increased sympathetic drive, leading to an
aberrant activation of high-threshold muscle afferents [35].
Moreover, the A11-diencephalic dopaminergic nucleus has a
close anatomical relationship with the suprachiasmatic
nucleus, a key structure for circadian rhythms [36], and
represents a relay between this and the spinal cord [3].
(erefore, the hypothesis can be made that in RLS, there is a
fluctuating disinhibition of the nociceptive system, due to an
impairment of the descending control structures. Second, a
dysfunction in the production of melatonin, a hormone that
has been associated with circadian modification of symp-
toms in other conditions, such as migraine and cluster
headache [37], could have a role. (ird, there could be a
contribution of the cortical excitability variations. Circadian
modifications of the cortical excitability have been described
in normal subjects [38] and in RLS, both in humans [39] and
in animal models [40]. In this view, the nocturnal increase in
corticospinal excitability in RLS could account for both the
motor disturbances and the increased pain sensitivity.
We have to mention a limitation of our study. Indeed,
most our patients showed a high periodic limb movement
(PLM) index. (erefore, we cannot be sure to what extent
our findings could be related to PLM, rather than to RLS.
However, PLM have been found in 80–89% of RLS patients
[41]; thus, the dissociation between RLS and PLM is very
difficult to investigate.
5. Conclusions
To the best of our knowledge, this is the first study evaluating
nociceptive system in RLS patients, according to the cir-
cadian pattern of the symptoms. Our study confirms the
structural integrity of Aδ nociceptive system in idiopathic
RLS. However, RLS patients show an abnormal circadian
modification of Aδ-fiber pathway excitability, possibly due
to an impairment of the hypothalamic dopaminergic pro-
jections to the spinal cord.
Data Availability
(e neurophysiological laser-evoked potential data used to
support the findings of this study are available from the
corresponding author upon request.
Table 5: Neurophysiological data: night/day ratio.
Foot Hand
N1 latency RLS 94.2± 10.6 U test: 69
p � 0.151
98.8± 21.7 U test: 68
p � 0.622CTR 99.8± 12.5 95.7± 10.3
N1 amplitude RLS 133.9± 50.4 U test: 82
p � 0.016∗
135.2± 124.5 U test: 65
p � 0.768CTR 83.7± 34.5 87.5± 41.4
N2 latency RLS 100.3± 13.7 U test: 35
p � 0.257
95.2± 16.3 U test: 52
p � 0.577CTR 106.0± 12.0 103.5± 14.9
P2 latency RLS 106.2± 12.6 U test: 69
p � 0.577
96.8± 6.6 U test: 52
p � 0.577CTR 103.6± 8.2 99.4± 9.1
N2-P2 amplitude RLS 119.2± 15.6 U test: 106
p � 0.003∗
100.2± 35.5 U test: 76
p � 0.309CTR 88.4± 23.4 86.2± 22.6
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